Clinical Research, Pharma & Healthcare FinancingRondo Therapeutics Publishes Preclinical Data on RNDO-564 TherapyBusiness WireApril 8, 2025April 9, 2025 by Business WireApril 8, 2025April 9, 2025026 RNDO-564 is designed to deliver safe and robust tumor killing activity in Nectin-4 positive tumors. RNDO-564 utilizes a novel mechanism of action for the treatment...
